Sharon Mates Sells 53,013 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates sold 53,013 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $80,970,388.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Sharon Mates also recently made the following trade(s):

• On Friday, August 23rd, Sharon Mates sold 28,680 shares of Intra-Cellular Therapies stock. The shares were sold at an average price of $74.46, for a total transaction of $2,135,512.80.

Intra-Cellular Therapies Stock Performance

ITCI traded up $0.12 on Friday, reaching $74.48. 268,108 shares of the company’s stock were exchanged, compared to its average volume of 973,190. Intra-Cellular Therapies, Inc. has a twelve month low of $45.50 and a twelve month high of $84.89. The company’s 50 day moving average is $74.93 and its 200-day moving average is $71.07. The company has a market cap of $7.86 billion, a price-to-earnings ratio of -64.16 and a beta of 1.01.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.03. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The company had revenue of $161.40 million during the quarter, compared to the consensus estimate of $157.74 million. During the same quarter last year, the company earned ($0.45) earnings per share. Intra-Cellular Therapies’s revenue for the quarter was up 45.7% on a year-over-year basis. Sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.54 EPS for the current year.

Analyst Ratings Changes

ITCI has been the topic of a number of recent research reports. Royal Bank of Canada reduced their target price on shares of Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Mizuho upped their target price on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a report on Friday, June 21st. UBS Group reduced their target price on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. The Goldman Sachs Group cut their price objective on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Finally, Canaccord Genuity Group increased their price objective on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

Institutional Trading of Intra-Cellular Therapies

A number of hedge funds have recently made changes to their positions in the stock. Kapitalo Investimentos Ltda bought a new position in Intra-Cellular Therapies during the fourth quarter worth $26,000. Headlands Technologies LLC bought a new stake in Intra-Cellular Therapies in the first quarter valued at $32,000. Signaturefd LLC lifted its stake in Intra-Cellular Therapies by 85.7% in the fourth quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 239 shares during the last quarter. Fidelis Capital Partners LLC bought a new stake in Intra-Cellular Therapies in the first quarter valued at $53,000. Finally, Summit Securities Group LLC bought a new stake in Intra-Cellular Therapies in the second quarter valued at $56,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.